nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—S100A1—ganglion—peripheral nervous system neoplasm	0.033	0.192	CbGeAlD
Olopatadine—S100B—nerve—peripheral nervous system neoplasm	0.0289	0.168	CbGeAlD
Olopatadine—S100B—ganglion—peripheral nervous system neoplasm	0.0285	0.166	CbGeAlD
Olopatadine—S100A2—parotid gland—peripheral nervous system neoplasm	0.0166	0.0965	CbGeAlD
Olopatadine—S100A1—trigeminal ganglion—peripheral nervous system neoplasm	0.0162	0.0942	CbGeAlD
Olopatadine—S100A12—trigeminal ganglion—peripheral nervous system neoplasm	0.0142	0.0824	CbGeAlD
Olopatadine—S100B—brainstem—peripheral nervous system neoplasm	0.0124	0.072	CbGeAlD
Olopatadine—S100A13—Vitamin A—Isotretinoin—peripheral nervous system neoplasm	0.0102	0.363	CbGdCrCtD
Olopatadine—S100A13—Vitamin A—Tretinoin—peripheral nervous system neoplasm	0.0102	0.363	CbGdCrCtD
Olopatadine—S100A13—Vitamin A—Alitretinoin—peripheral nervous system neoplasm	0.00775	0.275	CbGdCrCtD
Olopatadine—S100A1—cerebellum—peripheral nervous system neoplasm	0.00708	0.0411	CbGeAlD
Olopatadine—Amitriptyline—NTRK2—peripheral nervous system neoplasm	0.00699	0.463	CrCbGaD
Olopatadine—S100A13—cerebellum—peripheral nervous system neoplasm	0.00628	0.0365	CbGeAlD
Olopatadine—S100B—cerebellum—peripheral nervous system neoplasm	0.00611	0.0355	CbGeAlD
Olopatadine—Amitriptyline—NTRK1—peripheral nervous system neoplasm	0.00432	0.286	CrCbGaD
Olopatadine—S100A2—p73 transcription factor network—NTRK1—peripheral nervous system neoplasm	0.0043	0.0787	CbGpPWpGaD
Olopatadine—S100A2—Validated transcriptional targets of TAp63 isoforms—CDKN2A—peripheral nervous system neoplasm	0.00308	0.0562	CbGpPWpGaD
Olopatadine—HRH1—trigeminal ganglion—peripheral nervous system neoplasm	0.00287	0.0167	CbGeAlD
Olopatadine—S100A2—Direct p53 effectors—HGF—peripheral nervous system neoplasm	0.00238	0.0435	CbGpPWpGaD
Olopatadine—S100A2—Direct p53 effectors—MET—peripheral nervous system neoplasm	0.00188	0.0343	CbGpPWpGaD
Olopatadine—S100A12—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—IFNB1—peripheral nervous system neoplasm	0.00171	0.0313	CbGpPWpGaD
Olopatadine—S100B—Nuclear signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.00162	0.0296	CbGpPWpGaD
Olopatadine—S100B—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—IFNB1—peripheral nervous system neoplasm	0.00162	0.0296	CbGpPWpGaD
Olopatadine—S100A2—p73 transcription factor network—MYC—peripheral nervous system neoplasm	0.00154	0.0281	CbGpPWpGaD
Olopatadine—Muscle spasms—Cisplatin—peripheral nervous system neoplasm	0.00112	0.00154	CcSEcCtD
Olopatadine—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.00112	0.00153	CcSEcCtD
Olopatadine—Infection—Alitretinoin—peripheral nervous system neoplasm	0.00111	0.00152	CcSEcCtD
Olopatadine—Immune system disorder—Etoposide—peripheral nervous system neoplasm	0.00111	0.00152	CcSEcCtD
Olopatadine—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.00111	0.00152	CcSEcCtD
Olopatadine—Eye pain—Epirubicin—peripheral nervous system neoplasm	0.0011	0.00151	CcSEcCtD
Olopatadine—Vision blurred—Cisplatin—peripheral nervous system neoplasm	0.0011	0.00151	CcSEcCtD
Olopatadine—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.0011	0.0015	CcSEcCtD
Olopatadine—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.0011	0.0015	CcSEcCtD
Olopatadine—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.00109	0.00149	CcSEcCtD
Olopatadine—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.00109	0.00149	CcSEcCtD
Olopatadine—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.00109	0.00149	CcSEcCtD
Olopatadine—Ill-defined disorder—Cisplatin—peripheral nervous system neoplasm	0.00108	0.00148	CcSEcCtD
Olopatadine—Oedema—Vincristine—peripheral nervous system neoplasm	0.00108	0.00148	CcSEcCtD
Olopatadine—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.00107	0.00147	CcSEcCtD
Olopatadine—Infection—Vincristine—peripheral nervous system neoplasm	0.00107	0.00147	CcSEcCtD
Olopatadine—Asthenia—Topotecan—peripheral nervous system neoplasm	0.00107	0.00146	CcSEcCtD
Olopatadine—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.00106	0.00145	CcSEcCtD
Olopatadine—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.00106	0.00145	CcSEcCtD
Olopatadine—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.00106	0.00145	CcSEcCtD
Olopatadine—Malaise—Cisplatin—peripheral nervous system neoplasm	0.00105	0.00144	CcSEcCtD
Olopatadine—Pruritus—Topotecan—peripheral nervous system neoplasm	0.00105	0.00144	CcSEcCtD
Olopatadine—Dysgeusia—Etoposide—peripheral nervous system neoplasm	0.00105	0.00143	CcSEcCtD
Olopatadine—Asthenia—Melphalan—peripheral nervous system neoplasm	0.00104	0.00143	CcSEcCtD
Olopatadine—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.00104	0.00143	CcSEcCtD
Olopatadine—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.00104	0.00143	CcSEcCtD
Olopatadine—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.00104	0.00142	CcSEcCtD
Olopatadine—Back pain—Etoposide—peripheral nervous system neoplasm	0.00103	0.00142	CcSEcCtD
Olopatadine—Pain—Dactinomycin—peripheral nervous system neoplasm	0.00103	0.00141	CcSEcCtD
Olopatadine—Pruritus—Melphalan—peripheral nervous system neoplasm	0.00103	0.00141	CcSEcCtD
Olopatadine—Muscle spasms—Etoposide—peripheral nervous system neoplasm	0.00103	0.00141	CcSEcCtD
Olopatadine—Eye pain—Doxorubicin—peripheral nervous system neoplasm	0.00102	0.0014	CcSEcCtD
Olopatadine—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00102	0.00139	CcSEcCtD
Olopatadine—S100A12—TRAF6 Mediated Induction of proinflammatory cytokines—PTPN11—peripheral nervous system neoplasm	0.00102	0.0186	CbGpPWpGaD
Olopatadine—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.00101	0.00138	CcSEcCtD
Olopatadine—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.00101	0.00138	CcSEcCtD
Olopatadine—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000997	0.00137	CcSEcCtD
Olopatadine—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000996	0.00137	CcSEcCtD
Olopatadine—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000994	0.00136	CcSEcCtD
Olopatadine—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.000994	0.00136	CcSEcCtD
Olopatadine—Ill-defined disorder—Etoposide—peripheral nervous system neoplasm	0.000992	0.00136	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000987	0.00135	CcSEcCtD
Olopatadine—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000986	0.00135	CcSEcCtD
Olopatadine—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000983	0.00135	CcSEcCtD
Olopatadine—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.000982	0.00135	CcSEcCtD
Olopatadine—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000976	0.00134	CcSEcCtD
Olopatadine—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000976	0.00134	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000965	0.00132	CcSEcCtD
Olopatadine—Malaise—Etoposide—peripheral nervous system neoplasm	0.000964	0.00132	CcSEcCtD
Olopatadine—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000964	0.00132	CcSEcCtD
Olopatadine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—PTPN11—peripheral nervous system neoplasm	0.00096	0.0176	CbGpPWpGaD
Olopatadine—Pain—Alitretinoin—peripheral nervous system neoplasm	0.000956	0.00131	CcSEcCtD
Olopatadine—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000953	0.00131	CcSEcCtD
Olopatadine—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000953	0.00131	CcSEcCtD
Olopatadine—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000953	0.00131	CcSEcCtD
Olopatadine—Infection—Cisplatin—peripheral nervous system neoplasm	0.000946	0.0013	CcSEcCtD
Olopatadine—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000946	0.0013	CcSEcCtD
Olopatadine—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000938	0.00129	CcSEcCtD
Olopatadine—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000938	0.00129	CcSEcCtD
Olopatadine—Rash—Topotecan—peripheral nervous system neoplasm	0.000938	0.00128	CcSEcCtD
Olopatadine—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000937	0.00128	CcSEcCtD
Olopatadine—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000934	0.00128	CcSEcCtD
Olopatadine—Cough—Etoposide—peripheral nervous system neoplasm	0.000933	0.00128	CcSEcCtD
Olopatadine—Headache—Topotecan—peripheral nervous system neoplasm	0.000932	0.00128	CcSEcCtD
Olopatadine—Rash—Tretinoin—peripheral nervous system neoplasm	0.00093	0.00127	CcSEcCtD
Olopatadine—Rash—Isotretinoin—peripheral nervous system neoplasm	0.00093	0.00127	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.00093	0.00127	CcSEcCtD
Olopatadine—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000929	0.00127	CcSEcCtD
Olopatadine—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000929	0.00127	CcSEcCtD
Olopatadine—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000929	0.00127	CcSEcCtD
Olopatadine—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000926	0.00127	CcSEcCtD
Olopatadine—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000925	0.00127	CcSEcCtD
Olopatadine—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000924	0.00127	CcSEcCtD
Olopatadine—Headache—Tretinoin—peripheral nervous system neoplasm	0.000924	0.00127	CcSEcCtD
Olopatadine—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000921	0.00126	CcSEcCtD
Olopatadine—Pain—Vincristine—peripheral nervous system neoplasm	0.000921	0.00126	CcSEcCtD
Olopatadine—S100A12—MyD88 cascade initiated on plasma membrane—PTPN11—peripheral nervous system neoplasm	0.000919	0.0168	CbGpPWpGaD
Olopatadine—Rash—Melphalan—peripheral nervous system neoplasm	0.000918	0.00126	CcSEcCtD
Olopatadine—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000917	0.00126	CcSEcCtD
Olopatadine—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000914	0.00125	CcSEcCtD
Olopatadine—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000912	0.00125	CcSEcCtD
Olopatadine—S100A12—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—PTPN11—peripheral nervous system neoplasm	0.00091	0.0166	CbGpPWpGaD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000904	0.00124	CcSEcCtD
Olopatadine—Discomfort—Etoposide—peripheral nervous system neoplasm	0.0009	0.00123	CcSEcCtD
Olopatadine—S100A12—MyD88 dependent cascade initiated on endosome—PTPN11—peripheral nervous system neoplasm	0.000893	0.0163	CbGpPWpGaD
Olopatadine—Clomipramine—ABCB1—peripheral nervous system neoplasm	0.000893	0.0592	CrCbGaD
Olopatadine—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.00089	0.00122	CcSEcCtD
Olopatadine—Chlorprothixene—ABCB1—peripheral nervous system neoplasm	0.000889	0.0589	CrCbGaD
Olopatadine—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000888	0.00122	CcSEcCtD
Olopatadine—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000884	0.00121	CcSEcCtD
Olopatadine—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000884	0.00121	CcSEcCtD
Olopatadine—Nausea—Topotecan—peripheral nervous system neoplasm	0.000883	0.00121	CcSEcCtD
Olopatadine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000881	0.0161	CbGpPWpGaD
Olopatadine—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000881	0.00121	CcSEcCtD
Olopatadine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000876	0.0012	CcSEcCtD
Olopatadine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000876	0.0012	CcSEcCtD
Olopatadine—S100B—MyD88 cascade initiated on plasma membrane—PTPN11—peripheral nervous system neoplasm	0.000869	0.0159	CbGpPWpGaD
Olopatadine—Infection—Etoposide—peripheral nervous system neoplasm	0.000867	0.00119	CcSEcCtD
Olopatadine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000865	0.00119	CcSEcCtD
Olopatadine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000865	0.00119	CcSEcCtD
Olopatadine—S100A12—Toll Like Receptor 9 (TLR9) Cascade—PTPN11—peripheral nervous system neoplasm	0.000862	0.0158	CbGpPWpGaD
Olopatadine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—PTPN11—peripheral nervous system neoplasm	0.00086	0.0157	CbGpPWpGaD
Olopatadine—Influenza—Epirubicin—peripheral nervous system neoplasm	0.00086	0.00118	CcSEcCtD
Olopatadine—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000852	0.00117	CcSEcCtD
Olopatadine—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000852	0.00117	CcSEcCtD
Olopatadine—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000849	0.00116	CcSEcCtD
Olopatadine—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000848	0.00116	CcSEcCtD
Olopatadine—S100A12—MyD88:Mal cascade initiated on plasma membrane—PTPN11—peripheral nervous system neoplasm	0.000847	0.0155	CbGpPWpGaD
Olopatadine—S100B—MyD88 dependent cascade initiated on endosome—PTPN11—peripheral nervous system neoplasm	0.000845	0.0154	CbGpPWpGaD
Olopatadine—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000844	0.00116	CcSEcCtD
Olopatadine—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000825	0.00113	CcSEcCtD
Olopatadine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000824	0.00113	CcSEcCtD
Olopatadine—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000824	0.00113	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000822	0.00113	CcSEcCtD
Olopatadine—S100B—Toll Like Receptor 9 (TLR9) Cascade—PTPN11—peripheral nervous system neoplasm	0.000815	0.0149	CbGpPWpGaD
Olopatadine—Pain—Cisplatin—peripheral nervous system neoplasm	0.000815	0.00112	CcSEcCtD
Olopatadine—S100A12—MyD88-independent cascade—PTPN11—peripheral nervous system neoplasm	0.000813	0.0149	CbGpPWpGaD
Olopatadine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000802	0.0011	CcSEcCtD
Olopatadine—S100B—MyD88:Mal cascade initiated on plasma membrane—PTPN11—peripheral nervous system neoplasm	0.000801	0.0147	CbGpPWpGaD
Olopatadine—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.0008	0.0011	CcSEcCtD
Olopatadine—S100A2—Direct p53 effectors—TP53—peripheral nervous system neoplasm	0.000799	0.0146	CbGpPWpGaD
Olopatadine—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000796	0.00109	CcSEcCtD
Olopatadine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000794	0.00109	CcSEcCtD
Olopatadine—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000791	0.00108	CcSEcCtD
Olopatadine—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000785	0.00108	CcSEcCtD
Olopatadine—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000783	0.00107	CcSEcCtD
Olopatadine—Doxepin—ABCB1—peripheral nervous system neoplasm	0.000783	0.0519	CrCbGaD
Olopatadine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000778	0.00107	CcSEcCtD
Olopatadine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000776	0.00106	CcSEcCtD
Olopatadine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000773	0.00106	CcSEcCtD
Olopatadine—S100B—MyD88-independent cascade—PTPN11—peripheral nervous system neoplasm	0.000769	0.0141	CbGpPWpGaD
Olopatadine—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000767	0.00105	CcSEcCtD
Olopatadine—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000767	0.00105	CcSEcCtD
Olopatadine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000767	0.00105	CcSEcCtD
Olopatadine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000765	0.00105	CcSEcCtD
Olopatadine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.00076	0.00104	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000753	0.00103	CcSEcCtD
Olopatadine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000753	0.00103	CcSEcCtD
Olopatadine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000752	0.00103	CcSEcCtD
Olopatadine—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000748	0.0137	CbGpPWpGaD
Olopatadine—Pain—Etoposide—peripheral nervous system neoplasm	0.000746	0.00102	CcSEcCtD
Olopatadine—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000746	0.00102	CcSEcCtD
Olopatadine—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000746	0.00102	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.00074	0.00101	CcSEcCtD
Olopatadine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000739	0.00101	CcSEcCtD
Olopatadine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000737	0.00101	CcSEcCtD
Olopatadine—S100A12—Activated TLR4 signalling—PTPN11—peripheral nervous system neoplasm	0.000731	0.0134	CbGpPWpGaD
Olopatadine—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000724	0.000993	CcSEcCtD
Olopatadine—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000724	0.000991	CcSEcCtD
Olopatadine—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.00072	0.000986	CcSEcCtD
Olopatadine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000719	0.000985	CcSEcCtD
Olopatadine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000716	0.000981	CcSEcCtD
Olopatadine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000714	0.000978	CcSEcCtD
Olopatadine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000712	0.000976	CcSEcCtD
Olopatadine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000711	0.000974	CcSEcCtD
Olopatadine—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.00071	0.000972	CcSEcCtD
Olopatadine—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.00071	0.000972	CcSEcCtD
Olopatadine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000705	0.000966	CcSEcCtD
Olopatadine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000704	0.000965	CcSEcCtD
Olopatadine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000702	0.000962	CcSEcCtD
Olopatadine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.0007	0.00096	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—CD55—peripheral nervous system neoplasm	0.000697	0.0127	CbGpPWpGaD
Olopatadine—S100B—Activated TLR4 signalling—PTPN11—peripheral nervous system neoplasm	0.000692	0.0126	CbGpPWpGaD
Olopatadine—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.00069	0.000946	CcSEcCtD
Olopatadine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.00069	0.000945	CcSEcCtD
Olopatadine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.00069	0.000945	CcSEcCtD
Olopatadine—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.00069	0.000945	CcSEcCtD
Olopatadine—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.00069	0.000945	CcSEcCtD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—PTPN11—peripheral nervous system neoplasm	0.000688	0.0126	CbGpPWpGaD
Olopatadine—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000685	0.000939	CcSEcCtD
Olopatadine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000685	0.000939	CcSEcCtD
Olopatadine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000684	0.000937	CcSEcCtD
Olopatadine—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000683	0.000936	CcSEcCtD
Olopatadine—Rash—Vincristine—peripheral nervous system neoplasm	0.000679	0.000931	CcSEcCtD
Olopatadine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000679	0.00093	CcSEcCtD
Olopatadine—Headache—Vincristine—peripheral nervous system neoplasm	0.000675	0.000925	CcSEcCtD
Olopatadine—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000669	0.000917	CcSEcCtD
Olopatadine—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000666	0.000912	CcSEcCtD
Olopatadine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000664	0.00091	CcSEcCtD
Olopatadine—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000664	0.000909	CcSEcCtD
Olopatadine—S100B—Innate Immune System—CD55—peripheral nervous system neoplasm	0.000659	0.012	CbGpPWpGaD
Olopatadine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000652	0.000893	CcSEcCtD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—PTPN11—peripheral nervous system neoplasm	0.000651	0.0119	CbGpPWpGaD
Olopatadine—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000644	0.000882	CcSEcCtD
Olopatadine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000643	0.000881	CcSEcCtD
Olopatadine—Nausea—Vincristine—peripheral nervous system neoplasm	0.00064	0.000877	CcSEcCtD
Olopatadine—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000639	0.000875	CcSEcCtD
Olopatadine—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000634	0.000869	CcSEcCtD
Olopatadine—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000632	0.000866	CcSEcCtD
Olopatadine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000626	0.000858	CcSEcCtD
Olopatadine—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000622	0.000852	CcSEcCtD
Olopatadine—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000621	0.00085	CcSEcCtD
Olopatadine—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000617	0.000846	CcSEcCtD
Olopatadine—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000614	0.000841	CcSEcCtD
Olopatadine—S100A12—Toll-Like Receptors Cascades—PTPN11—peripheral nervous system neoplasm	0.000613	0.0112	CbGpPWpGaD
Olopatadine—Imipramine—ABCB1—peripheral nervous system neoplasm	0.000609	0.0404	CrCbGaD
Olopatadine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000606	0.00083	CcSEcCtD
Olopatadine—Amitriptyline—ABCB1—peripheral nervous system neoplasm	0.000605	0.0401	CrCbGaD
Olopatadine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000601	0.000823	CcSEcCtD
Olopatadine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.0006	0.000822	CcSEcCtD
Olopatadine—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000599	0.000821	CcSEcCtD
Olopatadine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000597	0.000818	CcSEcCtD
Olopatadine—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000595	0.000816	CcSEcCtD
Olopatadine—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000587	0.000804	CcSEcCtD
Olopatadine—Back pain—Epirubicin—peripheral nervous system neoplasm	0.00058	0.000794	CcSEcCtD
Olopatadine—S100B—Toll-Like Receptors Cascades—PTPN11—peripheral nervous system neoplasm	0.000579	0.0106	CbGpPWpGaD
Olopatadine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000577	0.000791	CcSEcCtD
Olopatadine—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000576	0.00079	CcSEcCtD
Olopatadine—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000575	0.000789	CcSEcCtD
Olopatadine—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000574	0.000787	CcSEcCtD
Olopatadine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000566	0.000775	CcSEcCtD
Olopatadine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000565	0.000774	CcSEcCtD
Olopatadine—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000556	0.000762	CcSEcCtD
Olopatadine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000555	0.00076	CcSEcCtD
Olopatadine—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000555	0.00076	CcSEcCtD
Olopatadine—Rash—Etoposide—peripheral nervous system neoplasm	0.00055	0.000754	CcSEcCtD
Olopatadine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.00055	0.000753	CcSEcCtD
Olopatadine—Headache—Etoposide—peripheral nervous system neoplasm	0.000547	0.000749	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.000546	0.00998	CbGpPWpGaD
Olopatadine—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000543	0.000744	CcSEcCtD
Olopatadine—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000541	0.000741	CcSEcCtD
Olopatadine—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000537	0.000735	CcSEcCtD
Olopatadine—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000533	0.000731	CcSEcCtD
Olopatadine—Cough—Epirubicin—peripheral nervous system neoplasm	0.000523	0.000717	CcSEcCtD
Olopatadine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000523	0.000716	CcSEcCtD
Olopatadine—Nausea—Etoposide—peripheral nervous system neoplasm	0.000518	0.00071	CcSEcCtD
Olopatadine—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000515	0.000705	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—PPP3R1—peripheral nervous system neoplasm	0.000508	0.00929	CbGpPWpGaD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000507	0.000694	CcSEcCtD
Olopatadine—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000504	0.000691	CcSEcCtD
Olopatadine—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.0005	0.000685	CcSEcCtD
Olopatadine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000499	0.000684	CcSEcCtD
Olopatadine—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000489	0.00067	CcSEcCtD
Olopatadine—Infection—Epirubicin—peripheral nervous system neoplasm	0.000486	0.000666	CcSEcCtD
Olopatadine—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000484	0.000663	CcSEcCtD
Olopatadine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000482	0.00882	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—PPP3R1—peripheral nervous system neoplasm	0.000481	0.00879	CbGpPWpGaD
Olopatadine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.00048	0.000657	CcSEcCtD
Olopatadine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000475	0.000651	CcSEcCtD
Olopatadine—HRH1—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000473	0.00864	CbGpPWpGaD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000469	0.000643	CcSEcCtD
Olopatadine—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000467	0.000639	CcSEcCtD
Olopatadine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000462	0.000633	CcSEcCtD
Olopatadine—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000453	0.00062	CcSEcCtD
Olopatadine—Infection—Doxorubicin—peripheral nervous system neoplasm	0.00045	0.000616	CcSEcCtD
Olopatadine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000444	0.000608	CcSEcCtD
Olopatadine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.00044	0.000602	CcSEcCtD
Olopatadine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000436	0.000598	CcSEcCtD
Olopatadine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000435	0.000596	CcSEcCtD
Olopatadine—HRH1—IL-4 Signaling Pathway—BIRC5—peripheral nervous system neoplasm	0.000435	0.00795	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—ERBB2—peripheral nervous system neoplasm	0.000431	0.00788	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000423	0.00773	CbGpPWpGaD
Olopatadine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000422	0.000579	CcSEcCtD
Olopatadine—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000422	0.000578	CcSEcCtD
Olopatadine—Pain—Epirubicin—peripheral nervous system neoplasm	0.000418	0.000573	CcSEcCtD
Olopatadine—S100A12—Immune System—CD55—peripheral nervous system neoplasm	0.000406	0.00742	CbGpPWpGaD
Olopatadine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000404	0.000553	CcSEcCtD
Olopatadine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000403	0.000552	CcSEcCtD
Olopatadine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000402	0.000551	CcSEcCtD
Olopatadine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.0004	0.000548	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000391	0.000535	CcSEcCtD
Olopatadine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.00039	0.000535	CcSEcCtD
Olopatadine—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000387	0.00053	CcSEcCtD
Olopatadine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000387	0.00053	CcSEcCtD
Olopatadine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000387	0.00053	CcSEcCtD
Olopatadine—S100B—Immune System—CD55—peripheral nervous system neoplasm	0.000384	0.00702	CbGpPWpGaD
Olopatadine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000373	0.000511	CcSEcCtD
Olopatadine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.00037	0.000507	CcSEcCtD
Olopatadine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.00036	0.000494	CcSEcCtD
Olopatadine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000358	0.00049	CcSEcCtD
Olopatadine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000358	0.00049	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—IFNB1—peripheral nervous system neoplasm	0.000352	0.00644	CbGpPWpGaD
Olopatadine—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000351	0.000481	CcSEcCtD
Olopatadine—HRH1—IL-4 Signaling Pathway—PTPN11—peripheral nervous system neoplasm	0.000349	0.00638	CbGpPWpGaD
Olopatadine—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000346	0.000474	CcSEcCtD
Olopatadine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000335	0.000459	CcSEcCtD
Olopatadine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000334	0.000457	CcSEcCtD
Olopatadine—S100B—Innate Immune System—IFNB1—peripheral nervous system neoplasm	0.000333	0.00609	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—NRAS—peripheral nervous system neoplasm	0.000328	0.006	CbGpPWpGaD
Olopatadine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000325	0.000445	CcSEcCtD
Olopatadine—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000324	0.000443	CcSEcCtD
Olopatadine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.00032	0.000439	CcSEcCtD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000313	0.00572	CbGpPWpGaD
Olopatadine—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000311	0.000426	CcSEcCtD
Olopatadine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.00031	0.000424	CcSEcCtD
Olopatadine—Rash—Epirubicin—peripheral nervous system neoplasm	0.000308	0.000423	CcSEcCtD
Olopatadine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000308	0.000422	CcSEcCtD
Olopatadine—S100A12—Immune System—CD34—peripheral nervous system neoplasm	0.000308	0.00562	CbGpPWpGaD
Olopatadine—Headache—Epirubicin—peripheral nervous system neoplasm	0.000306	0.00042	CcSEcCtD
Olopatadine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000299	0.00041	CcSEcCtD
Olopatadine—S100A12—Immune System—PPP3R1—peripheral nervous system neoplasm	0.000296	0.00541	CbGpPWpGaD
Olopatadine—S100B—Immune System—CD34—peripheral nervous system neoplasm	0.000291	0.00532	CbGpPWpGaD
Olopatadine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000291	0.00531	CbGpPWpGaD
Olopatadine—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000291	0.000398	CcSEcCtD
Olopatadine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000288	0.000394	CcSEcCtD
Olopatadine—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000285	0.000391	CcSEcCtD
Olopatadine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000285	0.000391	CcSEcCtD
Olopatadine—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000284	0.000389	CcSEcCtD
Olopatadine—S100B—Immune System—PPP3R1—peripheral nervous system neoplasm	0.00028	0.00512	CbGpPWpGaD
Olopatadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000277	0.00506	CbGpPWpGaD
Olopatadine—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000368	CcSEcCtD
Olopatadine—S100A12—Immune System—NCAM1—peripheral nervous system neoplasm	0.000262	0.00478	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000259	0.00473	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000248	0.00454	CbGpPWpGaD
Olopatadine—S100B—Immune System—NCAM1—peripheral nervous system neoplasm	0.000247	0.00452	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	0.00024	0.00439	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000238	0.00436	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000229	0.00418	CbGpPWpGaD
Olopatadine—HRH1—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000212	0.00388	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	0.000212	0.00387	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IFNB1—peripheral nervous system neoplasm	0.000205	0.00375	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—PTPN11—peripheral nervous system neoplasm	0.000198	0.00363	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000196	0.00359	CbGpPWpGaD
Olopatadine—S100B—Immune System—IFNB1—peripheral nervous system neoplasm	0.000194	0.00355	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.00019	0.00347	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—PTPN11—peripheral nervous system neoplasm	0.000188	0.00343	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000181	0.00331	CbGpPWpGaD
Olopatadine—S100A12—Immune System—HGF—peripheral nervous system neoplasm	0.000158	0.0029	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—ERBB2—peripheral nervous system neoplasm	0.000157	0.00287	CbGpPWpGaD
Olopatadine—S100B—Immune System—HGF—peripheral nervous system neoplasm	0.00015	0.00274	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—ERBB2—peripheral nervous system neoplasm	0.000148	0.00271	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000141	0.00257	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000136	0.00249	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000135	0.00248	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000135	0.00246	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000122	0.00224	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—NRAS—peripheral nervous system neoplasm	0.000119	0.00218	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000117	0.00214	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000116	0.00213	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PTPN11—peripheral nervous system neoplasm	0.000116	0.00211	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000115	0.00211	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—NRAS—peripheral nervous system neoplasm	0.000113	0.00206	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000111	0.00203	CbGpPWpGaD
Olopatadine—S100B—Immune System—PTPN11—peripheral nervous system neoplasm	0.000109	0.002	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000107	0.00196	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000102	0.00187	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000102	0.00186	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	9.37e-05	0.00171	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	9.27e-05	0.0017	CbGpPWpGaD
Olopatadine—S100A12—Immune System—ERBB2—peripheral nervous system neoplasm	9.14e-05	0.00167	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.73e-05	0.0016	CbGpPWpGaD
Olopatadine—S100B—Immune System—ERBB2—peripheral nervous system neoplasm	8.64e-05	0.00158	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	8.56e-05	0.00156	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.26e-05	0.00151	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.71e-05	0.00141	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.29e-05	0.00133	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NTS—peripheral nervous system neoplasm	7.23e-05	0.00132	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.07e-05	0.00129	CbGpPWpGaD
Olopatadine—S100A12—Immune System—NRAS—peripheral nervous system neoplasm	6.95e-05	0.00127	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	6.94e-05	0.00127	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CD55—peripheral nervous system neoplasm	6.93e-05	0.00127	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.88e-05	0.00126	CbGpPWpGaD
Olopatadine—S100B—Immune System—NRAS—peripheral nervous system neoplasm	6.57e-05	0.0012	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.05e-05	0.00111	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.59e-05	0.00102	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	5.5e-05	0.00101	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.48e-05	0.001	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.29e-05	0.000968	CbGpPWpGaD
Olopatadine—S100A12—Immune System—HRAS—peripheral nervous system neoplasm	5.08e-05	0.00093	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	5.08e-05	0.000929	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.07e-05	0.000927	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.06e-05	0.000924	CbGpPWpGaD
Olopatadine—S100B—Immune System—HRAS—peripheral nervous system neoplasm	4.81e-05	0.000879	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.81e-05	0.000879	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.64e-05	0.000849	CbGpPWpGaD
Olopatadine—S100A12—Immune System—AKT1—peripheral nervous system neoplasm	4.49e-05	0.000821	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.25e-05	0.000777	CbGpPWpGaD
Olopatadine—S100B—Immune System—AKT1—peripheral nervous system neoplasm	4.25e-05	0.000776	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.96e-05	0.000724	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.8e-05	0.000694	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	3.36e-05	0.000614	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.34e-05	0.000611	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.25e-05	0.000594	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.25e-05	0.000594	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	3.22e-05	0.000589	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.11e-05	0.000568	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	3.1e-05	0.000567	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.1e-05	0.000566	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.84e-05	0.000519	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.74e-05	0.000502	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	2.03e-05	0.000372	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.01e-05	0.000367	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.97e-05	0.000361	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.72e-05	0.000314	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.64e-05	0.0003	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.62e-05	0.000295	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.56e-05	0.000285	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.47e-05	0.000269	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.43e-05	0.000261	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.42e-05	0.000259	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.32e-05	0.000241	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.3e-05	0.000237	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.29e-05	0.000237	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.19e-05	0.000217	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.11e-05	0.000202	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.08e-06	0.000166	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.68e-06	0.000159	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.67e-06	0.00014	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	3.56e-06	6.51e-05	CbGpPWpGaD
